-
PBS Liposomes for Reliable Macrophage Controls
2026-09-01
PBS Liposomes provide a non-depleting, phagocytosis-compatible comparator for separating clodronate-specific macrophage loss from effects caused by liposome delivery. This workflow-focused guide explains how to pair phosphate-buffered saline liposomes with clodronate liposomes, standardize handling, and troubleshoot ambiguous in vivo results.
-
TRPM3 Regulation by Neurosteroids and Primidone
2026-09-01
Yin et al. combine cryo-electron microscopy, electrophysiology, molecular dynamics, and mass spectrometry to define how pregnenolone sulfate, CIM0216, and primidone regulate TRPM3. The resulting ligand-binding and gating framework connects TRPM3 pharmacology with nociception, neurodevelopmental disease, and structure-guided inhibitor design.
-
OSMI-1 Workflow for O-GlcNAcylation Research
2026-08-31
OSMI-1 provides a cell-permeable way to test how OGT-dependent protein modification shapes trophoblast stress, iron handling, and ferroptosis. This practical guide combines dose-finding, Nup62-based target engagement, HUWE1–TfR1 pathway analysis, and troubleshooting for cleaner mechanistic conclusions.
-
CKI 7 dihydrochloride: CK1 Workflows
2026-08-31
Build cleaner CK1 perturbation experiments with CKI 7 dihydrochloride, from concentration-controlled cell assays to pathway-specific validation. The workflow also shows how to use the compound alongside, rather than as a substitute for, mechanistic studies of phosphorylation, ubiquitination, and cancer-cell invasion.
-
Okadaic acid (A4540): PP1/PP2A Workflow Guide
2026-08-30
Okadaic acid (A4540) provides controlled inhibition of PP2A at low nanomolar potency and PP1 at higher concentrations, helping researchers connect phosphatase activity with phosphorylation-dependent signaling and apoptosis endpoints. It is appropriate for defined biochemical and cell-based experiments, but should not be treated as a broad phosphatase inhibitor or used without vehicle, concentration, and assay-specific controls.
-
DIDS and the Ion Biology of Metastatic Escape
2026-08-29
DIDS offers translational researchers a mechanistic probe for connecting chloride transport, cell-death recovery, stress signaling, and tumor-state plasticity. This thought-leadership perspective explains how to use DIDS without mistaking broad pharmacology for single-target proof, while translating findings on PAMEs and PIMs into stronger experimental strategies.
-
Vardenafil HCl Trihydrate in PDE5 Assays
2026-08-28
Vardenafil HCl Trihydrate combines nanomolar PDE5 potency with a practical solubility profile for enzyme, tissue, and cGMP signaling studies. This guide shows how to translate its selectivity into reproducible smooth muscle relaxation workflows while using native proteoform analysis to frame off-target questions.
-
Y-27632 Workflows for Patient-Derived Organoids
2026-08-28
Y-27632 is a practical ROCK inhibitor for separating dissociation-related cytoskeletal stress from genuine changes in organoid growth and drug response. This workflow applies selective ROCK1/2 inhibition to patient-derived breast organoids while preserving the controls needed for interpretable cancer biology research.
-
H-89: cAMP-Dependent Protein Kinase Inhibitor
2026-08-27
H-89 is a cAMP-dependent protein kinase inhibitor used to interrogate protein kinase A inhibition and cAMP signaling pathway modulation. The supplier-reported biochemical IC50 is 48 nM, but cellular activity and selectivity require assay-specific validation and off-target controls.
-
circRHOBTB3–NONO–MAOA in Prostate Cancer
2026-08-27
The reference study identifies circRHOBTB3 as a prostate cancer suppressor that retains NONO in the cytoplasm, thereby reducing MAOA transcription and limiting proliferation and metastasis. Its integrated analysis of circRNA expression, RNA–protein interactions, transcriptional control, and animal models provides a mechanistic framework for metastatic prostate cancer research and biomarker development.
-
Ezh2–p53 Control of Neat1 in Inflammasome Activation
2026-08-26
The reference study identifies a methyltransferase-independent role for Ezh2 in maintaining H3K27 acetylation at the Neat1 promoter, enabling p65-dependent transcription and inflammasome activation. It also defines a counter-regulatory p53–SIRT1 pathway, offering a mechanistic framework for understanding how epigenetic competition controls ASC oligomerization and downstream inflammatory signaling.
-
BHQ for Calcium Signaling and SERCA Research
2026-08-26
BHQ provides a practical way to perturb SERCA-dependent calcium handling, connect ER calcium depletion with downstream signaling, and test pathway-specific hypotheses. This guide translates BHQ into reproducible calcium imaging, vascular physiology, and hematopoietic stem cell workflows while emphasizing controls for solvent, redox, and cell-stress effects.
-
Obacunone, Akt/p53, and Ferroptosis in Ovarian Cancer
2026-08-25
The reference study identifies an Akt/p53-dependent mechanism through which obacunone promotes ferroptosis and suppresses ovarian cancer cell growth. By combining cellular, biochemical, mitochondrial, and xenograft analyses with Fer-1 and SC79 pathway perturbation, the work links Akt inhibition to impaired antioxidant defense and increased lipid peroxidation.
-
1-Phenyl-2-Pentanol and Hepatic Fibrosis
2026-08-25
The reference study identified 1-Phenyl-2-pentanol from Moringa oleifera leaves and evaluated its ability to suppress activation of human hepatic stellate cells in vitro. Its combined gene, protein, proteomic, and molecular-docking evidence supports inhibition of TGF-β1- and Wnt/β-catenin-associated fibrotic signaling, while the compound’s distinction from Fenipentol must be maintained.
-
O-GlcNAcylation Rewires Wnt-Driven Bone Formation
2026-08-24
The reference study identifies O-GlcNAcylation as a required metabolic and signaling intermediate in Wnt3a-stimulated osteoblastogenesis. Its central mechanistic finding is that Wnt3a modifies PDK1 at Ser174, stabilizing PDK1, increasing aerobic glycolysis, and supporting bone formation and fracture repair.